Last reviewed · How we verify
Lacosamide - conventional titration
Lacosamide enhances slow inactivation of voltage-gated sodium channels, thereby stabilizing neuronal membranes and reducing seizure activity.
Lacosamide enhances slow inactivation of voltage-gated sodium channels, thereby stabilizing neuronal membranes and reducing seizure activity. Used for Partial-onset seizures (adjunctive therapy), Primary generalized tonic-clonic seizures (adjunctive therapy).
At a glance
| Generic name | Lacosamide - conventional titration |
|---|---|
| Sponsor | Seoul National University Hospital |
| Drug class | Antiepileptic drug (AED) |
| Target | Voltage-gated sodium channels (slow inactivation enhancer) |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Lacosamide is a functionalized amino acid that selectively enhances slow inactivation of voltage-gated sodium channels, which reduces repetitive neuronal firing and prevents seizure propagation. Unlike conventional sodium channel blockers, it does not significantly affect fast inactivation, resulting in a more favorable safety profile. This mechanism makes it effective as an adjunctive antiepileptic agent.
Approved indications
- Partial-onset seizures (adjunctive therapy)
- Primary generalized tonic-clonic seizures (adjunctive therapy)
Common side effects
- Dizziness
- Headache
- Diplopia (double vision)
- Nausea
- Ataxia (loss of coordination)
- Tremor
- Blurred vision
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: